login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Research funded by the ALS Association found gene mutations can cause amyotrophic lateral sclerosis and other brain, muscle and bone diseases


Tuesday, 05 Mar 2013 14:17
J Paul Taylor
J Paul Taylor

Researchers supported by The ALS Association have discovered how mutations in new amyotrophic lateral sclerosis (ALS) genes cause not only ALS but also other diseases of the brain, muscle and bone, according to a release on 3 March 2013,. The results also shed light on the disease pathways of ALS due to other genes and may set the stage for development of new treatments to interrupt these processes. The study was published in the journal Nature.


ALS, also known as Lou Gehrig’s Disease in the USA, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. There is currently no known cause of the disease.

The research was led by J Paul Taylor, Department of Developmental Neurobiology at St Jude Children’s Research Hospital in Memphis, USA, and colleagues. They received funding through The ALS Association’s TREAT ALS (Translational research advancing therapies) programme.


The researchers discovered that mutations in genes for certain RNA-binding proteins cause them to switch between alternate shapes and aggregate, and to promote the same conformational change and aggregation of the normal protein. This behaviour has been seen in other neurodegenerative diseases, collectively called prion diseases, including mad cow disease and Creutzfeldt-Jakob disease. In those diseases, this ability leads to spread of the disease throughout the nervous system.

“This discovery may lead us to think more broadly about how ALS progresses within the brain and to ask whether a similar spreading process is occurring,” said Lucie Bruijn, chief scientist for The ALS Association.

The researchers also found that mutations in proteins called heterogeneous ribonuclear proteins (hnRNPs) caused an inherited disease in a small number of families with symptoms of ALS, the frontotemporal dementia, the muscle disease inclusion body myopathy, and the bone disorder Paget’s disease of bone. This cluster of symptoms, according to the study, has recently been recognised as a unique disorder called multisystem proteinopathy. The mutations increased the tendency of the hnRNP proteins to clump together and to induce non-mutated forms of the protein to do so as well. hnRNP proteins normally link to another ALS-associated protein called TDP-43, and the two were found together in the aggregates.

“While these mutations are themselves a very rare cause of ALS, they may provide an important clue about how other forms of ALS spread over time,” Bruijn said. “Preventing protein aggregation may be a viable therapeutic approach for many forms of ALS.”


Normal hnRNPA2 (left) and Mutant hnRNPA2 (right)
Normal hnRNPA2 (left) and Mutant hnRNPA2 (right)


Add New Comment

Related Items


Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions